Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Anti-tumor Activity of PB101 in Advanced Solid Tumors
NCT06075849Phase 1Recruiting
- Sponsor
- Panolos Bioscience
- Start
- Oct 2023
- Primary completion
- Oct 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VEGF-Grab in solid tumor (advanced stage), gastric cancer (GC), hepatocellular carcinoma (HCC) and 1 more, sponsored by Panolos Bioscience. Primary endpoints: Dose Limiting Toxicity at 8 weeks, Permanent discontinuation / dose reduction due to adverse events at 8 weeks and 3 more. Started Oct 2023; status: recruiting.
02
Drugs
VEGF-Grab
03
Conditions
solid tumor (advanced stage)gastric cancer (GC)hepatocellular carcinoma (HCC)metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06075849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06075849.